RecruitingNCT07381894

Multicentre Hypertrophic Cardiomyopathy Registry


Sponsor

University of Manchester

Enrollment

2,500 participants

Start Date

Apr 1, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to blockages in blood flow (left ventricular outflow tract obstruction), shortness of breath, and an increased risk of heart failure or sudden cardiac arrest. While standard treatments exist and new targeted medications (cardiac myosin inhibitors) have recently been approved, doctors still need better data to predict which treatments will work best for each individual patient. This national registry based in the UK is a secure database that collects health information from HCM patients across multiple NHS hospital sites in the UK over several years. Participants in this study will have their routine health information collected from their medical records, including details from heart scans (echocardiograms and MRIs), blood tests, and genetic information. With this HCM registry, we aim to improve disease understanding and risk prediction, paving the way for more personalised treatment plans for the HCM community in the future


Eligibility

Min Age: 18 YearsMax Age: 99 Years

Inclusion Criteria1

  • Confirmed diagnosis of Hypertrophic Cardiomyopathy (HCM) clinically and not solely explained by abnormal loading conditions (e.g., significant hypertension, valvular disease

Exclusion Criteria1

  • Participants who do not fulfil the imaging and clinical diagnostic criteria of HCM

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

University of Manchester

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07381894


Related Trials